Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046136 · ClinicalTrials.gov registry record · Phase 2
Mucinex Exploratory Cold Study
A Phase 2 study, sponsored by Reckitt Benckiser.
- Completed
- Registry status
- Phase 2
- Development phase
- 378
- Enrollment target
NCT01046136: Completed Phase 2 study, sponsored by Reckitt Benckiser.
NCT01046136 is a Phase 2 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 378 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (184% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01046136, a Phase 2 study, has completed, sponsored by Reckitt Benckiser.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 378 participants
- Enrollment target
Study Summary
This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
Primary Outcome
Yes the investigator would use this treatment for cold symptoms in the future.
Interventions
- DRUG placebo
- DRUG guaifenesin (Mucinex)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2009-12 |
| Phase | Phase 2 |
What the finished NCT01046136 record still lists
NCT01046136 is an interventional study that assigns participants to a tested intervention. The registered 378 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (184% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01046136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01046136 about?
NCT01046136 is a clinical study titled "Mucinex Exploratory Cold Study". This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
What is the current status of trial NCT01046136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 378 participants. The study started on 2009-12.
What interventions are being tested in trial NCT01046136?
The interventions under investigation include: placebo (DRUG), guaifenesin (Mucinex) (DRUG).
Who is sponsoring clinical trial NCT01046136?
This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01046136's enrollment target sits among peer trials
378 115th of 2000 higher than 1,886 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia